Strattera is not an SSRI. It belongs to a completely different drug class called selective norepinephrine reuptake inhibitors (SNRIs), and it works on a different brain chemical than SSRIs do. Strattera is FDA-approved exclusively for treating ADHD in children (ages 6 and up) and adults, while SSRIs are prescribed for depression, anxiety, and other mood disorders.
How Strattera Works Differently From SSRIs
SSRIs (like Prozac, Zoloft, and Lexapro) increase serotonin levels in the brain by blocking serotonin from being reabsorbed by nerve cells. Strattera does something similar mechanically, but with a different target. It blocks the norepinephrine transporter on nerve cells, preventing norepinephrine from being reabsorbed. This raises norepinephrine levels in the gaps between neurons, particularly in the prefrontal cortex, the part of the brain responsible for attention, decision-making, and impulse control.
Strattera has little or no affinity for either the serotonin or dopamine transporters. That’s a key distinction. It’s highly selective for norepinephrine, which is why it helps with focus and attention rather than mood regulation. Interestingly, because norepinephrine transporters in the prefrontal cortex also handle some dopamine cleanup, Strattera raises dopamine levels in that specific brain region too. But it doesn’t increase dopamine in the reward-related areas of the brain, which is an important part of why it doesn’t carry abuse risk.
Why People Confuse Strattera With SSRIs
The confusion makes sense for a few reasons. Both SSRIs and Strattera are reuptake inhibitors, meaning they work by blocking the recycling of a neurotransmitter back into the nerve cell. Both come in capsule form, are taken daily, and build up in the body over weeks before reaching full effectiveness. And unlike stimulant ADHD medications, Strattera doesn’t produce an immediately noticeable effect, which makes it “feel” more like an antidepressant to patients.
Adding to the confusion, the abbreviation SNRI is also used for a class of antidepressants (serotonin-norepinephrine reuptake inhibitors like Effexor and Cymbalta). But those drugs target both serotonin and norepinephrine, while Strattera targets norepinephrine alone. Despite sharing an acronym in some contexts, they’re pharmacologically distinct.
Strattera’s Timeline for Results
Like SSRIs, Strattera doesn’t work overnight. You may notice small improvements in ADHD symptoms within one to two weeks, but clinically meaningful improvement typically takes four to six weeks at the target dose. After that initial response, symptoms can continue improving gradually over 10 to 26 weeks of treatment. This slow ramp-up is one reason some people feel underwhelmed early on, especially if they’re comparing it to stimulant medications that work within an hour.
Clinicians generally recommend waiting at least four to six weeks at the target dose before judging whether Strattera is working.
Side Effects Compared to SSRIs
Because Strattera and SSRIs affect different neurotransmitter systems, their side effect profiles don’t overlap much. Common Strattera side effects include headache, abdominal pain, nausea, vomiting, decreased appetite, weight loss, irritability, insomnia, and sedation. The appetite suppression and weight loss are notable because some SSRIs are associated with weight gain over time.
Strattera carries a boxed warning (the FDA’s most serious safety label) about increased risk of suicidal thinking in children and adolescents. In pooled clinical trial data, suicidal ideation occurred in 0.4% of young patients taking Strattera compared to none taking a placebo. No suicides occurred in those trials. SSRIs carry a similar boxed warning for the same age groups, which is another reason the two drugs get mentally grouped together.
There have also been rare postmarketing reports of severe liver injury with Strattera, including one case that required a liver transplant. Signs to watch for include yellowing of the skin or eyes, dark urine, upper right abdominal pain, or unexplained flu-like symptoms.
No Abuse Potential
One of the biggest practical differences between Strattera and stimulant ADHD medications is that Strattera is not a controlled substance. It’s completely unscheduled by the DEA, meaning it carries no recognized abuse potential. Stimulant medications like methylphenidate (Ritalin, Concerta) and amphetamines (Adderall, Vyvanse) are Schedule II controlled substances, the same classification as oxycodone and fentanyl in terms of regulatory oversight.
This isn’t just a regulatory technicality. In laboratory studies, even among people who actively preferred stimulant drugs, atomoxetine at doses up to 180 mg produced no euphoria and no stimulant-like effects. In animal studies, it didn’t function as a reinforcer, meaning animals wouldn’t self-administer it the way they would cocaine or methylphenidate. This low abuse profile makes Strattera a practical option for patients with a history of substance use or for situations where stimulant prescriptions are complicated by regulatory barriers.
When Strattera Is Chosen Over Stimulants
Stimulants remain the first-line treatment for ADHD because they work faster and have higher response rates. Strattera fills a different niche. It’s often considered when stimulants cause intolerable side effects like severe anxiety or insomnia, when there’s concern about substance misuse, when a patient needs 24-hour coverage without the peaks and valleys of stimulant dosing, or when coexisting conditions like tic disorders make stimulants a less ideal choice.
Because it isn’t an SSRI or any type of antidepressant, Strattera is not prescribed for depression or anxiety on its own. Some patients taking it for ADHD do report mild improvements in anxiety symptoms, likely because better attention and executive function reduce the daily stress that fuels anxious feelings. But that’s an indirect benefit, not the drug’s purpose.